Therapy Areas: Respiratory
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
28 September 2026 - Netherlands-based holding company QIAGEN N.V. (NYSE:QGEN) (Frankfurt Prime Standard:QIA) announced on Monday that it has received US Food and Drug Administration (FDA) clearance fo...
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
28 September 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday an expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 (Takeda ...
Akeso enrols first patient in global Phase III trial of cadonilimab vs nivolumab in first-line gastric cancer
28 September 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Sunday that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicentre Phase III head-t...
Astellas doses first patient in Phase 3 lung cancer study
24 September 2026 - Japanese pharmaceutical company Astellas Pharma Inc (TSE:4503) announced on Wednesday that the first patient has been dosed in a Phase 3 study evaluating setidegrasib, a novel, inv...
AstraZeneca's Trixeo Aerosphere approved in EU for asthma maintenance treatment
23 September 2026 - Biopharmaceutical company AstraZeneca (LSE: AZN) (STO: AZN) (NYSE: AZN) declared on Wednesday that it has received European Commission approval for Trixeo Aerosphere as a maintenan...
Insmed's ARIKAYCE sNDA granted priority review by FDA
21 September 2026 - Biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) disclosed on Monday that the US Food and Drug Administration has accepted its supplemental New Drug Application for ARI...